茶叶科学 ›› 2009, Vol. 29 ›› Issue (3): 173-190.doi: 10.13305/j.cnki.jts.2009.3.001
• • 下一篇
陈宗懋
收稿日期:
2009-03-23
修回日期:
2009-04-10
出版日期:
2009-06-15
发布日期:
2019-09-06
作者简介:
陈宗懋(1933— )男,浙江海盐人,博士生导师,研究员,中国工程院院士。E-mail:chenzm@mail.tricaas.com
CHEN Zong-mao
Received:
2009-03-23
Revised:
2009-04-10
Online:
2009-06-15
Published:
2019-09-06
摘要: 对茶叶抗癌研究的世界进展进行了分析和综述。从1987年日本富田熏最早报道茶叶提取物可以抑制人体癌细胞起,全世界约发表了4000~5000篇关于茶叶抗癌的研究论文。作者将这些研究分为四个阶段:八十年代后期到九十年代中期主要集中在活体外、活体内以及临床实验,九十年代中期到新世纪初主要在流行病学研究和抗癌机理的研究,新世纪初继续进行抗癌机理研究同时进行活性成分在动物和人体内的代谢、运转和归宿的研究,从2004年起开始了儿茶素类化合物的结构修饰和改造以期提高其生物可利用性和生物活性。本文重点对2003年以来的文献分流行病学实验、抗癌机理、儿茶素类化合物在动物和人体中代谢与归宿、儿茶素类化合物的结构修饰和改造与生物活性等几个方面进行了综述,并就茶叶抗癌的应用前景进行了讨论。
中图分类号:
陈宗懋. 茶叶抗癌研究二十年[J]. 茶叶科学, 2009, 29(3): 173-190. doi: 10.13305/j.cnki.jts.2009.3.001.
CHEN Zong-mao. Twenty Years Period in the Investigation on the Anticarcinogenic Activity of Tea[J]. Journal of Tea Science, 2009, 29(3): 173-190. doi: 10.13305/j.cnki.jts.2009.3.001.
[1] H Fujiki, et al. Cancer inhibition by green tea[J], Mutation Res., 1998, 402:307~310. [2] H Fujiki.Green tea: Health benefits as cancer preventive for humans[J], The Chemical Record, 2005, 5:119~132. [3] NT Zaveri.Green tea and its polyphenolic catechins: Medicinial uses in cancer and noncancer applications[J]. Life Science, 2006,78: 2073~2080 [4] ZHEN Yongsu, CHEN zongmao, CHENG Shujing, et al.Tea: Bioactivity and therapeutic potential[C], Pp267, Taylor & Francis,2002. [5] A W Wu & M C Yu. Tea, hormone-related cancers and endogenous hormone levels[J], Mol. Nutr.Food Res., 2006, 50:160~169. [6] K Nakachi, Eguchi H & Imai K., Can teatime increase one’s lifetime?[J], Ageing Res Rev, 2003, 2: 1~10. [7] Katiyar SK & Mukhtar H. Tea in chemoprevention of cancer. Epidemiological and experimental study[J], Internat. J of Oncology, 1996, 8:221~238. [8] CS Yang, et al. Possible mechanisms of the cancer-preventive activities of green tea[J], Mol.Nutr. Food Res., 2006, 50:170~175 [9] Bushman J L.Green tea and cancer in humans: a review of the literature[J], Nutr. Cancer, 1998, 31:151~159. [10] Kohlmeier L, et al. Tea and cancer prevention: an evaluation of the epidemiologic literature[J], Nutr. Cancer, 1997,27:1~13. [11] Higdon JV & Frei B. Tea catechins and polyphenols:health effects, metabolism and antioxidant functions[J]. Critical Rev. in Fd & Nutr., 2003, 43:89~143. [12] CS Yang, Lambert JD, Ju J, et al.Tea and cancer prevention: Molecular mechanisms and human ewlevance[J], Tocicol. & Appl. Pharmacol., 2007, 224:265~273. [13] Osanai, et al. Enantioselective synthesis and proteasome inhibition of A-ring analogs of (-)-EGCG,the active ingredient of green tea extract[J], Heterocycles, 2008, 76:485~505. [14] J Landau, et al. Cancer prevention by tea and tea constituents[A], in “Carcinogenic and anticarcinogenic Food Components”[C], Ed.by Wanda baer-Dubowska, CRC Taylor & Francis, pp.219~237,2005.15 [15] AH Wu & MC Yu. Tea hormone-related cancers and endogenous hormone levels[J], Mol.Nutr. Food res.,2006, 50: 160~169 [16] J Clark & M You. Chemoprevention of lung cancer by tea[J], Mol. Nutr. Food Res.,2006, 50: 144~151 [17] Mantena SK, et al. Orally administration green tea polyphenols prevent ultraviolet radiation-induced skin cancer in mice through activation of cytotoxic T cells and inhibition of angiogenesis in tumors[J]., J Nutr., 2005, 135:2871~2877. [18] Jankun J, Selman SH, Swiercz R, et al.Why drinking green tea could prevent cancer[J], Nature, 1997, 387: 561. [19] Hye-Kyung Na & Young-Joon Surh. Intracellular signaling network as a prime chemopreventive target of (-)epigallocatechin gallate[J]. Mol. Nutr. Food Res., 2006, 50:152~159. [20] Gupta S, et al. Molecular pathway for (-)EGCG-induced cell cycle arrest and apoptosis of human prostate carcinoma cells[J], Arch. Biochem. Biophys.,2003, 410:177~185. [21] S. Shankar, et al. Green tea polyphenols: biology and therapeutic implications in cancer[J], Frontiers in bioscience, 2007, 12:4881~4899. [22] D G Nagle, et al. Epigallocatechin-3-gallate(EGCG): Chemical and biomedical perspectives[J], Phytochemistry, 2006, 67:1849~1855. [23] Suganuma M,Okabe S, Kai Y, et al.Synergistic effects of (-)epigallocatechin gallate with sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9[J], Cancer Res., 1999, 59:44~47. [24] RA Hiipakkaet al.Structure-activity relationship for inhibition of human 5 α-reductase by poluphenols[J], Biochem. Pharmacol.,2002,63:1165~1176. [25] Weisburg JH, et al. In vitro cytotoxicity of EGCG and tea extracts to cancerous and normal cells from the human oral cavity[J], Basic Clin Pharmacol. Toxicol., 1997, 95:191~200. [26] 陈宗懋. 茶多酚类化合物抗癌的生物化学和分子生物学基础[J]. 茶叶科学, 2003, 23(2): 83~93. [27] JH Weisburger & Fung-Lung Chung. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols[J], Fd & Chem. Toxocol., 2002, 40:1145~1154 [28] YC Liang, et al. Inhibition of cyclin-depedent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)epigallocatechin-3-gallate[J], Biochem. Biophys. Res. Commun., 1999, 275:328~334. [29] Sah, J F, et al. Epigallocatechin gallate inhibits epidermal growth factor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases[J], J. Biol. Chem., 2004, 279:12755~12762. [30] Zhao Y, et al. Induction of apoptosis by epigallocatechin gallate via mitochondrial signal transduction pathway[J], Prev. Med., 2001, 39:1172~1179.31 [31] S Ermakova, Choi BY, Choi HS, et al.The intermediate filament protein Vimentin is a new target for Epigallocatechin gallate[J], J. Biol. Chem., 2005, 280:16882~16890. [32] Adhami V M, Ahmad N, Mukhtar H.Molecular targets for green tea in prostste cancer prevention[J], J Nutr, 2003, 133:2417S~2424S. [33] Puig, et al. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate(EGCG)and C75[J], Breast Cancer Res. Treat, 2007 (on line) [34] Van der Hof KH, et al. Consumption of green or black tea does not increase resistance of low density lipoprotein to oxidation in humans[J], Am. J Clin. Nutr.,1997, 66: 1125~1132 [35] Susan B, et al. Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials[J], Nutrition Reviews,2004, 62:204~211. [36] Yim DS, et al. Relationship between the Val158Met polymorphism of catechol-0-methyl transferase and breast cancer[J], Pharmacogenetics, 2001, 11:279~286. [37] Wu AH, et al. Tea intake, COMT genotype, and breast cancer in Asian-American women[J], Cancer Res. ,2003, 63:7526~7529. [38] T Sugiyama & Y Sadzuka. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents[J], Biochim. Biophys. Acta, 2003, 1653;47~59. [39] JD Lambert & CS Yang. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols[J], Mutation Res., 2003, 523-524:201~208. [40] Qin L, et al. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the P13K/Akt pathway and Bcl-2 family proteins[J], Biochem. Biophy. Res. Commun., 2007, 354:852~857. [41] U Bachrach & YC Wang. Cancer therapy and prevention by green tea: role of ornithine decarboxylase[J], Amino Acids, 2002, 22:1~13 [42] F Tosetti, et al. Angioprevention:angiogenesis is a common and key target for cancer chrmopreventive agents[J], FASEB J.,2002, 16:2~14. [43] S Garbisa, et al. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate[J], Cancer, 2001, 91:822~832 [44] Naasanil S, et al. Telomerase inhibition, telomere shortening and senescense of cancer cells by tea catechins[J],Biochem Biophys. Res., Commun., 1998, 249; 391~396. [45] Sohn OS, Surace A, Fiala ES, et al.Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male rat[J], Xenobiotica 1994,24:119~127. [46] Silverman N, et al. NF-KappaB signaling pathways in mammalian and insect innate immunity[J], Genes Dev., 2001, 15:2321~2342. [47] E Navarro-Peran, et al. The antifolate activity of tea catechins[J], Cancer Res., 2005, 65(6): 2059~2064. [48] Harland B.Caffeine and nutrition[J],Nutrition,2000, 16:522~526. [49] N Ahmad, et al. Nitric oxide synthase and skin tumor promotion[J], Biochem. Biophy. Res. Commun., 1997, 232:328~331. [50] Sartor Let al., (-)EGCG inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema and invasion[J], J Leuk.Biol., 2002, 71:71~79. [51] Lin YL, et al. EGCG blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nucluear factor-K B[J] Molec. Pharmacol., 1997,52:465~472. [52] Dong Z, et al. Inhiition of tumor-induced activator protein 1 activation and cell transformation by tea polyphenols[J], Cancer Res.1997, ,57:4414~4419. [53] Zhao Y, et al. Induction of apoptosis by epigallocatechin- 3-gallate via mitochondrial signal transduction pathway[J]., Prev. Med., 2004, 39:1172~1179. [54] RA Isbrucker, et al. Safety studies on epigallocatechin gallate (EGCG) preparation, Part I. Genotoxicity Food & Chem Toxicol, 2005, 44: 631~635. [55] R A Isbrucker, et al. Safety Studies on Epigallocatechin gallate (EGCG) preparations.Part 2.:Dermal, acute and short-term oxicity studies[J], Food & Chem. Toxicol.,2005, 44:636~650 [56] R A Isbrucker, et al. Safety Studies on Epigallocatechin gallate (EGCG) preparations.Part 3: Teratogenicity and reproductive toxicity studies in rats[J], Food & Chem. Toxicol., 2005,44:651~657. [57] Nijveldt R, et al. Flavonoids: a review of probable mechanisms of action and potrential applications[J], Am. J. Clin. Nutr., 2001, 74:418~425. [58] D S Barbosa.Green tea polyphenolic compounds and human health[J], J. Verbr. Lebensm., 2007, 2:407~413. [59] Hastak K, et al. Role of P53 and NF-kappaB in epigallocatechin gallate-induced apoptosis of LNCaP cell[J].,Oncogene, 2003 22:4851~4859. [60] Okabe S, Ochiai Y, Park K, et al. Modulation of gene expression by (-)-epigallocatechin gallate in PC-9 cells using a cDNA expression array[J], Biol. Pharmacol. Bull., 2001, 24:883~886. [61] Lee M J, Lambert JD, Prabhu S, et al. Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract[J], Cancer Epidemio. Biomark. & Prevent., 2004, 13:132~137. [62] Nakaqchi K, Eguchi H, Imai K.Can tea time increase one’s lifetime?[J] Ageing Resear. Rev.,2003, 2:1~10 [63] Gupta S, et al. Growth inhibition, cell cycle dysesgulation and induction of apoptosis by green tea constituent EGCG in androgen-sensitive and androgen-insensitive human prostste carcinoma cells[J], Toxicol. Appl. Pharmacol, 2000, 164:82~90 [64] Zingarelli Bet al, Nuclear factor-kB as a therapeutic target in critical care medicine[J], Crit. Care Med., 31(suppl 1):2003, S 105~S 111. [65] Cao Y &, Cao R.Angiogenesis inhibited by drinking tea[J], Nature, 1999, 398:381 [66] Esteller M, et al. A gene hypermethylation profile of human cancer[J], Cancer Res., 2001, 61:3225~3229. [67] Ferrara N.Molecular and biological properties of vascular endothelial growth factors[J]. J Molecular Medicine, 1999,77:527~543 [68] A Kojima-Yuasa, et al. Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors[J], Life Sci., 2003, 73:1299~1313 [69] Jung YD —LM Ellis, EGCG, a major component of green tea, inhibits tumor growth by inhibiting VEGF induction in human colon carcinoma cells[J]., Brit. J of Cancer, 2001, 84:844~850. [70] G Fassina, et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate[J], Clin. Cancer Res, 2004, 10:4865~4873. [71] Mantena SK, et al. Epigallocatechin gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors[J]. Photochem. Photobiol., 2004, 81:1174~1179. [72] K Matsubara, et al. Epicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis[J], Life Sci., 2007, 80:1578~1585. [73] W Y Feng.Metabolism of green tea catechins: An overview, Current Drug Metabolism[J], 2006, 7: 755~809. [74] Chow HH, Cai Y, Hakim, IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals[J], Clin. Cancer Res., 2003, 9:3312~3319. [75] L Chen, Lee MJ, Li H, et al. Absorption, distribution and elimination of tea polyphenols in rats[J], Drug Metabol. Disp.,1997, 9:1045~1050. [76] Lambert JD, Lee MJ, Lu H, et al. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice.[J], J N ut., 2003, 133:4172~4177. [77] Nakagawa K & Miyazawa T. Absorption and distribution of tea catechin, (-)-epigallocatechin gallate, in the rat[J], J Nut. Sci. Vitaminol.,(Tokyo), 1997, 43: 679~684. [78] H, Chow, Cai Y, Albert DS, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E[J]., Cancer Epidemiol. Biomarkers Prev., 2001, 10:53~58. [79] H-H S Chow, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals[J], Clin. Cancer Res., 2005, 11:4627~4733. [80] C Linpinski, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings[J]. Adv. Drug Deliv. Rev., 2001, 46:3~26. [81] C Yang, Chen L, Lee MJ, et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers[J]., Cancer Epidemiol. Biomarkers Prev., 1998, 7:351~354. [82] JG Hengstler, et al. Can drinking tea present cancrer?[J] Arch. Toxicol., 2008, 82:(published online:09 Dec. 2008) [83] Lee MJ, et al. Analysis of plasma and urinary tea polyphenols in human subjects[J], Cancer, Epidemiol. Biomarkers Prev., 1995, 4:393~399. [84] Lee MJ, Maliakal P, Chen L, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability[J]., Cancer Epidemiol. Biomarkers Prev., 2002, 11: 1025~1032. [85] Yang C S, Lee MJ, Chen L.Human salivary tea catechin levels and catechin esterase activities;implication in human cancer prevention studies[J], Cancer Epidemiol. Biom ark. Prev., 1999, 8:83~89. [86] Li L & Chan TH. Enantioselective synthesis of EGCG, the active polyphenol component from green tea[J], Org. Lett., 2001, 3:739~741 [87] J George, et al. Tea: age-old beverage as an effective cancer chemopreventive agent[J], Oncol Rev., 2008, 1:243~252. [88] Yang CS .Inhibition of carcinogenesis by tea[J], Nature, 1997, 389,134~135. [89] Wan SB, D Chen, QP Dou, et al. Study of the green tea polyphenols CG and ECG as proteasome inhibitors[J], Bioorg. Med Chem., 2004, 12:3521~3527. [90] Hou Cet al.The challenge of developing green tea polyphenols as therapeutic agents[J], Inflammopharmacology, 2008, 16:1~5. [91] N Khan & H Mukhtar Tea polyphenols for health promotion[J], Life Sci., 2007, 81:519~533. [92] JD Lambert, et al. possible controversy over dietary polyphenols: benefits vs risks[J], Chem. Res. Toxicol., 2007, 20:583~585. [93] KR Landis-Piwowar, C Huo, D Chen, et al. A novel prodrug of the green tea polyphenol (-)-Epigallocatechin-3-gallate as apotent anticancer agent[J], Cancer Res., 2007, 67:4303~4310. [94] SC Lee, WK Chan, TW Lee, et al. Effect of a prodrug of the green tea polyphenol (-)-Epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo[J], Nutr. & Cancer, 2008, 60;483~491. [95] QP Dou, KR Landis-Piwowar, D Chen, et al. Green tea polyphenols as a natural tumour cell proteasome inhibitor[J], Inflammopharm, 2008, 16:1~5 [96] C Huo, G Shi, WH Lam, et al. Semi-synthesis and proteasome inhibition of D-ring deoxy analogs of (-)-epigallocatechin gallate (EGCG), the active ingredient of green tea extract[J],Can. J Chem., 2008, 86: 495~502. [97] BT Utenova, KE Malterud & F Rise. Antioxidant activity of O-protected derivatives of (-)-epigallocatechin-3-gallate: inhibition of soybean and rabbit 15-lipoxygenases[J], ARKIVOC, 2007, 9:6~16. [98] Wan SB, KR Landis-Piwowar, DJ Kuhn, et al. Structure-activity study of EGCG analogs as proteasome inhibitors[J], Bioorg Med. Chem., 2005, 13:2177~2185. [99] Wan SB, et al. Regiospecific and enantioselective synthesis of methylaed metabolites of tea catechins[J], Tetrahedron, 2006,62:5897~5904. [100] Osanai, Huo KR, Landis-Piwowar, et al. A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer[J], Bioorganic & Medic. Chem., 2007, 15:5076~5082. [101] K Nakagawa, et al. Antioxidative activity of 3-O-Octanoyl-(+)-catechin, a newly synthesized catechin, in vitro.[J], J. Health Sci., 2005, 51:492~496. [102] N Katunuma, et al. Catechin derivatives: specific inhibitor for caspases-3,7 and 2, and the prevention of apoptosis at the cell and animallevels[J], FEBS Letters, 2006, 580:741~746. [103] Haslam E.Natural polyphenols (vegetable tannins) as drugs: possible modes of action.[J], J Nat. Prod., 1996, 59:205~215. [104] Ullmann U,Haller J, Decourt JP, et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers[J]. J int. Med. Res., 2003,31:88~101. [105] Bettuzzi S, Brausi M, Rizzi, F, et al. Chemoprevention of human prostste cancer by oral administration of green tea catechins in volunmeers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study[J], Cancer Res., 2006, 66:1234~1240. [106] Kazi A, Wang Z, Kumar N, et al. Structure-activity relationships of synthetic analogs of (-)EGCG as proteasome inhibitors[J], Anticancer Res., 2004, 24:943~954. [107] Landis-Piwowar KR, Huo CD, Chen D, et al. Methyation suppresses the proteasome-inhibitory function of green tea polyphenols[J], J Cell Physiology, 2007, 213:252~260. [108] Lee SK, WK Chan, TW Lee, et al. Effect of a pro-drug of the green tea polyphenolEGCG on the growth of androgen independent prostate cancer in vitro[J], Nutri. Cancer,2008, 60:483~491. [109] Schilter Bet al., Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements[J], Food Chem. Toxicol., 2003, 41:1625~1649. [110] Yang CSet al.Antioxidative and anti-carcinogenic activities of tea polyphenols [J], Arch. Toxicol., 2008,82:(Accessed 12 Nov 2008). [111] K Matsubaraet alEpicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis[J], Life Sci.,2007, 80:1578~1585. [112] Galati G, et al. Cellular and in vitro hepatoxicity caused by green tea phenolic acids and catechins[J], Free radical Biol Med, 2006, 40:570~580. [113] S Uesato, et al. Inhibitory effects of 3-O-Acyl-(+)-catechins on Epstein-Barr virus activation[J], Chem Pharm Bull, 2003, 51:1448~1 [114] S Azam, et al. Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3- gallate: implications for anticancer properties[J]. Toxicology in vitro, 2006,18:555~561. [115] 杨贤强, 王岳飞, 陈留记, 等. 茶多酚的化学[C]. 上海: 上海科学技术出版社, 2003. [116] EC Stuart, et al. Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostste cancer[J], Life Sci.,2006, 79:2329~2336. [117] YC Wang & U Achrach. The specific anti-cancer activity of green tea (-)-epigallocatechin -3-gallate, Amino Acids[J], 2002, 22:131~143 [118] X Wang & W Tian. Green tea Epigallocatechin gallate: A natural inhibitor of fatty-acid synthase[J], Biochem. Biophy. Res. Communic., 2001, 288:1200~1206 [119] JD Lambert, Sang S, Hong J, et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of EGCG[J], Drug Metabol. & Disp., 2006, 34:2111~2115. [120] Khan SG, et al. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention[J], Cancer Res., 1992, 52:4050~4052. [121] YJ Surh.NF-kB and AP-1 as molecular targets for chemoprevention with EGCG, a review[J], Environ Chem Lett., 2006, 4:137~141. [122] C S Hofmann & G E Sonenshei., green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle via activation of p53[J], FASEB J, 2003,17:702~704. |
[1] | 陈宇宏, 高颖, 韩震, 尹军峰. 不同种质茶叶籽皂素含量及组成分析[J]. 茶叶科学, 2022, 42(5): 705-716. |
[2] | 李峥, 刘锭, 霍增辉, 陈富桥. 中国与RCEP成员国茶叶贸易竞争性与互补性分析[J]. 茶叶科学, 2022, 42(5): 740-752. |
[3] | 俞蓉欣, 郑芹芹, 陈红平, 张劲松, 张相春. 儿茶素生物医用纳米材料研究进展[J]. 茶叶科学, 2022, 42(4): 447-462. |
[4] | 王玉源, 刘任坚, 刘少群, 舒灿伟, 孙彬妹, 郑鹏. 茶树R2R3-MYB转录因子CsTT2表达分析及功能初步鉴定[J]. 茶叶科学, 2022, 42(4): 463-476. |
[5] | 李晶, 林彩容, 黄艳, 邓旭铭, 王艺清, 孙威江. 茶多酚对农杆菌介导的植物遗传转化体系的影响[J]. 茶叶科学, 2022, 42(4): 477-490. |
[6] | 方梦瑞, 吕军, 阮建云, 边磊, 武传宇, 姚青. 基于改进YOLOv4-tiny的茶叶嫩芽检测模型[J]. 茶叶科学, 2022, 42(4): 549-560. |
[7] | 刘奇, 欧阳建, 刘昌伟, 陈宏宇, 李娟, 熊立瑰, 刘仲华, 黄建安. 茶叶品质评价技术研究进展[J]. 茶叶科学, 2022, 42(3): 316-330. |
[8] | 向晶, 梁月荣, 赵东, 王开荣, 陆建良, 袁名安, 郑新强. 不同品种、地区茶叶籽仁含油量及茶叶籽油中脂肪酸组分和含量差异性分析[J]. 茶叶科学, 2022, 42(2): 233-248. |
[9] | 胡高华, 曹建荣, 杨蕾文宣, 王晨, 周苏娟, 刘新, 鲁成银, 陈红平, 马桂岑. 基于壳聚糖/氧化石墨烯/硅藻土固相萃取-液相色谱串联质谱测定茶叶中多种农药残留[J]. 茶叶科学, 2022, 42(2): 249-262. |
[10] | 疏再发, 郑生宏, 邵静娜, 周慧娟, 吉庆勇, 刘瑜, 何卫中, 王丽鸳. 不同茶树品种(系)对减半施肥的响应研究[J]. 茶叶科学, 2022, 42(2): 277-289. |
[11] | 吴芹瑶, 杨江帆, 林程, 管曦. 中国茶叶生产布局变迁研究[J]. 茶叶科学, 2022, 42(2): 290-300. |
[12] | 刘亚军, 王培强, 蒋晓岚, 庄菊花, 高丽萍, 夏涛. 茶树单体和聚合态儿茶素生物合成的研究进展[J]. 茶叶科学, 2022, 42(1): 1-17. |
[13] | 马冰凇, 王佳菜, 徐成成, 任小盈, 马存强, 周斌星. 不同仓储期普洱茶(生茶)中酚类成分差异及其对体外抗氧化能力的影响[J]. 茶叶科学, 2022, 42(1): 51-62. |
[14] | 周少锋, 乾云菲, 赵真, 陈暄, 黎星辉. 不同发酵程度茶叶对茶垢形成的影响[J]. 茶叶科学, 2022, 42(1): 76-86. |
[15] | 何文丽, 潘杉, 管曦. 可追溯茶叶产品的认知、信任与购买意愿研究[J]. 茶叶科学, 2022, 42(1): 140-150. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
|